🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adjuvant osimertinib (EGFR) and alectinib (ALK) are new standards in resectable NSCLC. Trials like NeoADAURA, ALNEO/NAUTIKA1 evaluate perioperative (neoadj/adj) TKIs in EGFR, ALK, KRAS G12C, BRAF, RET (LIBRETO 432), NTRK & MET ascopubs.org/doi/pdf/10.120…

ABSTRACT 8001: NeoADAURA. Neoadjuvant osi ± chemo vs chemo alone in resectable #EGFR NSCLC. Low MPR w/ chemo alone (2%) + equivalent MPR w/ osi or osi + chemo (25-26%). EFS tricky to parse given perioperative design. IMO, challenges role of neoadj chemo in resectable #EGFR #NSCLC

Five years into the CROWN study, this follow-up shows that #lorlatinib efficacy and safety in the Asian subgroup continue to be consistent with the overall population, according to Wu et al. 🔗 Read more: bit.ly/43CSWzf

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥Dynamic changes in target protein exp. following Tx in NSCLC: Simultaneous evaluation of MET, TROP2, HER2, B7-H4, and MDM2 in paired biopsies 🎙️ Dr. Saori Murata Hidehito HORINOUCHI 📌Poster Bd71, Abstr 8591 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC) 🎙️ Heather Wakelee 📌Poster Bd143, Abstr 8022 OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥TROPION-Lung14: A phase 3 study of osimertinib ± Dato-DXd as 1L Tx for pts with EGFR-m locally advanced or metastatic NSCLC 🎙️ Dr. Shun Lu 📌Poster Bd127a, Abstr TPS8647 🔢NCT06350097 OncoAlert ASCO EGFR Resisters LARVOL meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥Real world characteristics of stages II-III NSCLC patients (pts) who initiate neoadjuvant chemo-immunotherapy (NACT-I) and do not undergo surgical resection 🎙️ Jair Bar 📌Poster Bd140, Abstr 8019 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥CTONG 1804: Molecular profiling of neoadj immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of 🎙️ Dr. Si Yang Maggie Liu 📌Poster Bd146, Abstr 8025 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥NeoCOAST-2: Neoadjuvant durvalumab (D) + chemo + novel anticancer agents and adjuvant D ± novel agents in resectable NSCLC 🎙️ Dr. Tina Cascone 📌Poster Bd167, Abstr 8046 OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

Data from KRYSTAL-7: In 1L KRAS G12C-mutant NSCLC, #Adagrasib + #pembrolizumab showed ORR 44%, median DOR 26.3 mo, and PFS 11.0 mo across all PD-L1 levels. Enriched efficacy seen in PD-L1 ≥50%. Phase 3 trials ongoing. #ASCO25

#Zipalertinib in EGFR exon 20ins NSCLC - ORR: 35% in primary efficacy population, 40% post platinum chemo, 24% post amivantamab (+/- other exon20 targeted Tx; higher ORR at 30% if no prior other exon20 targeted Tx) - Median DOR: 8.8 mo overall - PFS: 9.4 mo overall #ASCO25

.Herbert Loong, MBBS, FASCO presents BAY088 (sevabertinib) cohort D/F. HER2 treatment naive/SACT naive. Cohort D, ORR=60.5% DOR 9.2mo (TKD ORR 65%). Cohort F, ORR 59%. AEs mostly GI/EGFR-related, 25% G3 diarrhea. Active drug but note skin/GI tox #ASCO25

Dr. Li Zhang at #ASCO25 with Opti-TROP-Lung03 with sacituzumab tirumotecan (Sac-TMT) in EGFR NSCLC post TKI and chemo randomized vs docetaxel. Sac-TMT superior: RR 45% vs 16%, PFS 6.9 vs 2.8m HR 0.30, OS immature but HR 0.49 (HR 0.36 adjusted for crossover). Approved in China.

In #AEGEAN, majority of patients with MRD+ NSCLC had persistent ctDNA during neoadjuvant therapy and experienced rapid relapse after surgery. KMT2C and KEAP1 mutations associated with MRD status. Can MRD assays identify pts who could benefit from treatment escalation? #ASCO25

🆕 #ASCO25 Abstracts 🆙 ☑️#LCSM Rapid Oral, Mets 🔥Phase 3 study of benmelstobart in comb with chemo followed by sequential comb with anlotinib for the 1L Tx of sq-NSCLC 🎙️ Dr. Yuankai Shi 🎯HR 0.64 (98.35CI 0.45-0.93) OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

☑️#ASCO25 🆙 ☑️#LCSM Rapid Oral, Mets 🔥Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory NSCLC 🎙️ Dr. Ling Zhou 🎯ORR 47%, DCR 87% 🎯Higher efficacy in pts with ≥30% CEA staining without brain mets OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

☑️#ASCO25 🆙 ☑️#LCSM Rapid Oral, Mets 🔥Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated NSCLC 🎙️ Dr. Rui Wang 🎯ORR 52.4%, DCR 87.6%, mPFS 7.2m OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

These results will confirm the restriction on nivolumab approval to PD-L1+ve patients in Europe by EU Medicines Agency previously based on EFS data. #ASCO25 #LCSM

NeoADAURA, Osi/osi-chemo/chemo neoadj 2 vs 8% PD rate MPR 26 vs 25 vs 2%: benefit across genotype & stage. Greater depth response by osi-chemo>osi Nodal downstaging in both osi arms Osi/osi-chemo reduces PD, gets MPR Impressive EFS by MPR vs not #ASCO25

☑️#ASCO25 🆙 ☑️#LCSM Oral, LocReg/SCLC 🔥R-ALPS: TQB2450 + /- anlotinib as maint Tx in pts with stage III NSCLC without progression following CRT 🎙️ Dr Ming Chen 🎯PFS 15.15 vs. 4.17m, HR 0.49 (0.36-0.66) OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…